Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination

Ping Zhou, Yana Zhang, Carmen Martinez, Nagesh Kalakonda, Stephen D Nimer, Raymond L. Comenzo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Optimal methods of stem cell mobilization in multiple myeloma are undefined, and contaminating clonotypic cells could contribute to disease recurrence. A phase 2 trial of intravenous melphalan (60 mg/m2) and granulocyte colony-stimulating factor (G-CSF) (10 μg/kg/d) for mobilization was performed. To enhance reliability, contamination was assessed with 2 sensitive methods, immunoglobulin light and heavy chain variable region patient-specific limiting-dilution polymerase chain reaction (PCR). We evaluated 29 stem cell components (SCCs) from 15 patients; for 9 SCCs, only VL PCR was used because of light chain disease or technical problems with VH primers. For 20 SCCs, VL and VH PCR results were highly correlated (r2 = 0.93, P < .01), with 35% (7 of 20) having identical estimates. VH PCR gave significantly higher estimates for 8 - and VL PCR for 5 - SCCs, supporting the utility of using 2 methods. Estimated clonotypic contamination per SCC was 0.0009% (range, 0%-0.1%) or 0.5 × 104 clonotypic cells per kilogram (range, 0-41.2 x 104/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P < .01). Melphalan-mobilized SCCs contain minimal clonotypic contamination.

Original languageEnglish
Pages (from-to)477-479
Number of pages3
JournalBlood
Volume102
Issue number2
DOIs
StatePublished - Jul 15 2003
Externally publishedYes

Fingerprint

Melphalan
Cellular Structures
Stem cells
Blood Cells
Polymerase chain reaction
Contamination
Blood
Stem Cells
Polymerase Chain Reaction
Hematopoietic Stem Cell Mobilization
Immunoglobulin Light Chains
Immunoglobulin Heavy Chains
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Dilution
Light
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. / Zhou, Ping; Zhang, Yana; Martinez, Carmen; Kalakonda, Nagesh; Nimer, Stephen D; Comenzo, Raymond L.

In: Blood, Vol. 102, No. 2, 15.07.2003, p. 477-479.

Research output: Contribution to journalArticle

Zhou, Ping ; Zhang, Yana ; Martinez, Carmen ; Kalakonda, Nagesh ; Nimer, Stephen D ; Comenzo, Raymond L. / Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. In: Blood. 2003 ; Vol. 102, No. 2. pp. 477-479.
@article{e27891c77feb4fa8ade759c01077e51c,
title = "Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination",
abstract = "Optimal methods of stem cell mobilization in multiple myeloma are undefined, and contaminating clonotypic cells could contribute to disease recurrence. A phase 2 trial of intravenous melphalan (60 mg/m2) and granulocyte colony-stimulating factor (G-CSF) (10 μg/kg/d) for mobilization was performed. To enhance reliability, contamination was assessed with 2 sensitive methods, immunoglobulin light and heavy chain variable region patient-specific limiting-dilution polymerase chain reaction (PCR). We evaluated 29 stem cell components (SCCs) from 15 patients; for 9 SCCs, only VL PCR was used because of light chain disease or technical problems with VH primers. For 20 SCCs, VL and VH PCR results were highly correlated (r2 = 0.93, P < .01), with 35{\%} (7 of 20) having identical estimates. VH PCR gave significantly higher estimates for 8 - and VL PCR for 5 - SCCs, supporting the utility of using 2 methods. Estimated clonotypic contamination per SCC was 0.0009{\%} (range, 0{\%}-0.1{\%}) or 0.5 × 104 clonotypic cells per kilogram (range, 0-41.2 x 104/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P < .01). Melphalan-mobilized SCCs contain minimal clonotypic contamination.",
author = "Ping Zhou and Yana Zhang and Carmen Martinez and Nagesh Kalakonda and Nimer, {Stephen D} and Comenzo, {Raymond L.}",
year = "2003",
month = "7",
day = "15",
doi = "10.1182/blood-2002-12-3674",
language = "English",
volume = "102",
pages = "477--479",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination

AU - Zhou, Ping

AU - Zhang, Yana

AU - Martinez, Carmen

AU - Kalakonda, Nagesh

AU - Nimer, Stephen D

AU - Comenzo, Raymond L.

PY - 2003/7/15

Y1 - 2003/7/15

N2 - Optimal methods of stem cell mobilization in multiple myeloma are undefined, and contaminating clonotypic cells could contribute to disease recurrence. A phase 2 trial of intravenous melphalan (60 mg/m2) and granulocyte colony-stimulating factor (G-CSF) (10 μg/kg/d) for mobilization was performed. To enhance reliability, contamination was assessed with 2 sensitive methods, immunoglobulin light and heavy chain variable region patient-specific limiting-dilution polymerase chain reaction (PCR). We evaluated 29 stem cell components (SCCs) from 15 patients; for 9 SCCs, only VL PCR was used because of light chain disease or technical problems with VH primers. For 20 SCCs, VL and VH PCR results were highly correlated (r2 = 0.93, P < .01), with 35% (7 of 20) having identical estimates. VH PCR gave significantly higher estimates for 8 - and VL PCR for 5 - SCCs, supporting the utility of using 2 methods. Estimated clonotypic contamination per SCC was 0.0009% (range, 0%-0.1%) or 0.5 × 104 clonotypic cells per kilogram (range, 0-41.2 x 104/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P < .01). Melphalan-mobilized SCCs contain minimal clonotypic contamination.

AB - Optimal methods of stem cell mobilization in multiple myeloma are undefined, and contaminating clonotypic cells could contribute to disease recurrence. A phase 2 trial of intravenous melphalan (60 mg/m2) and granulocyte colony-stimulating factor (G-CSF) (10 μg/kg/d) for mobilization was performed. To enhance reliability, contamination was assessed with 2 sensitive methods, immunoglobulin light and heavy chain variable region patient-specific limiting-dilution polymerase chain reaction (PCR). We evaluated 29 stem cell components (SCCs) from 15 patients; for 9 SCCs, only VL PCR was used because of light chain disease or technical problems with VH primers. For 20 SCCs, VL and VH PCR results were highly correlated (r2 = 0.93, P < .01), with 35% (7 of 20) having identical estimates. VH PCR gave significantly higher estimates for 8 - and VL PCR for 5 - SCCs, supporting the utility of using 2 methods. Estimated clonotypic contamination per SCC was 0.0009% (range, 0%-0.1%) or 0.5 × 104 clonotypic cells per kilogram (range, 0-41.2 x 104/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P < .01). Melphalan-mobilized SCCs contain minimal clonotypic contamination.

UR - http://www.scopus.com/inward/record.url?scp=0038156367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038156367&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-12-3674

DO - 10.1182/blood-2002-12-3674

M3 - Article

C2 - 12649134

AN - SCOPUS:0038156367

VL - 102

SP - 477

EP - 479

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -